(Q36615381)

15 August 2017

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials (English)

1 reference

15 August 2017

1 reference

D Cunningham

6

0 references

author name string

N R Maisey

1

1 reference

15 August 2017

A R Norman

2

1 reference

15 August 2017

A Hill

3

1 reference

15 August 2017

A Massey

4

1 reference

15 August 2017

J Oates

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

93

1 reference

15 August 2017

7

1 reference

15 August 2017

740-743

1 reference

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361637

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361637

Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361637

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361637

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361637

Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361637

Colorectal carcinoma antigens detected by hybridoma antibodies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361637

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361637

Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361637

Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361637

Nonparametric Estimation from Incomplete Observations

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602760

DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602760

Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis

21 January 2018

1 reference

12 December 2020

Prognostic value of microsatellite instability in resectable pancreatic cancer

1 reference

12 December 2020

Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer

1 reference

12 December 2020

Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas.

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6602760

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

16175188

1 reference